drugset / Trial / NCT04157140
Anlotinib In Combination With RFA And TACE in Patients With Middle-advanced HCC
NaSingle-groupOpen-labelTreatment
Summary
A single-arm, open-label clinical trial, focus on the safety and efficacy of anlotinib hydrochloride in combination with radiofrequency ablation (RFA) and transcatheter arterial chemoembolization(TACE) in patients with middle-advanced hepatocellular carcinoma(HCC)
Timeline
- Start
- 2019-11-28
- Primary completion
- 2022-09-01
- Completion
- 2023-03-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Catequentinib | Small molecule | 12 mg | Oral |